Download the presentation here: PDF
Download the presentation here: PDF
Download the presentation here: PDF
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
FAAH Pipeline<br />
JNJ-1661010 attenuates tactile<br />
allodynia in a rat mild <strong>the</strong>rmal<br />
injury model of acute tissue<br />
damage and in <strong>the</strong> rat spinal<br />
nerve ligation model of<br />
neuropathic pain. JNJ-1661010<br />
also diminishes <strong>the</strong>rmal<br />
hyperalgesia in <strong>the</strong> inflammatory<br />
rat carrageenan paw model.<br />
However, due to its irreversible<br />
binding to FAAH “These data<br />
suggest that FAAH inhibitors with<br />
modes of action similar to JNJ-<br />
1661010 may be useful clinically<br />
as broad-spectrum analgesics”.<br />
Anesth Analg.2009; 108: 316-329<br />
66<br />
Compound<br />
SSR 101010<br />
SSR411298<br />
KDS 4103<br />
ORG 231295<br />
OL-135<br />
FAAH Inhibitor<br />
JNJ 2883315<br />
JNJ 1661010<br />
RN-A<br />
RN-B<br />
FAAH Inhibitor<br />
Adis R&D Insight<br />
© Defined Health, 2009<br />
Pain Insight Briefing<br />
Developer<br />
sanofi-aventis<br />
sanofi-aventis<br />
Schering-Plough<br />
Schering-Plough<br />
Adolor Corporation<br />
Vernalis<br />
Johnson & Johnson<br />
Johnson & Johnson<br />
Evotec AG<br />
Evotec AG<br />
Infinity/Purdue/Mundipharma<br />
Phase<br />
I<br />
I<br />
Preclinical<br />
Preclinical<br />
Preclinical<br />
Preclinical<br />
Preclinical<br />
Preclinical<br />
Preclinical<br />
Preclinical<br />
Preclinical<br />
Indications<br />
Anxiety disorders, depression<br />
Anxiety disorders, depression<br />
Anxiety, depression, and pain<br />
Anxiety, depression, and pain<br />
Inflammatory pain<br />
Neuropathic pain<br />
Neuropathic pain<br />
Neuropathic pain<br />
Chronic pain<br />
Chronic pain<br />
Neuropathic pain
Change language